| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H23F3N2O4S |
| Molecular Weight | 504.521 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C1=C(CCC2=NOC3=CC(OCC(O)=O)=C(C)C=C23)SC(=N1)C4=CC=C(C=C4)C(F)(F)F
InChI
InChIKey=WWKYLBGQYALEDL-UHFFFAOYSA-N
InChI=1S/C25H23F3N2O4S/c1-13(2)23-21(35-24(29-23)15-4-6-16(7-5-15)25(26,27)28)9-8-18-17-10-14(3)19(33-12-22(31)32)11-20(17)34-30-18/h4-7,10-11,13H,8-9,12H2,1-3H3,(H,31,32)
| Molecular Formula | C25H23F3N2O4S |
| Molecular Weight | 504.521 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Senju Pharmaceutical is developing fonadelpar (also known as SJP-0035), a peroxisome proliferator activated receptor delta agonist as an ophthalmic solution. Fonadelpar was studied in phase III clinical trial in the USA for the treatment of patients with dry eye disease. This study was successfully completed. In addition, fonadelpar was involved in phase II clinical trial in the USA for the treatment of patients with moderate to severe corneal epithelial disorders. Besides, Senju Pharmaceutical also plans a phase II trial for corneal disorders in Japan.
